Vaxxinity : UB-312 Target Engagement - ADPD 2024

α

					UB-312
			Prasinezumab	Vaxxinity
	TAK-341 / MEDI1341	Roche / Prothena	126-135
	115-126
	AZ / Takeda
	102-130		LuAF82422	ABBV-0805
	BIIB54		Lundbeck	Abbvie
		112-117	121-127
	Biogen
	1-10
1	100				140
MDVFMKGLSK/AKEGV ------------------- GKNEEGAPQE/GILEDMPVDP/DNEAYEMPSE/EGYQDYEPEA
	alpha-synuclein amino acid sequence
					α
α		α

Α

							Placebo
		3.0					Group A
Titers	+ 95%CI					Group B
2.5
97-135
2.0
Anti-αSyn	LogDF,means
1.5
		1.0
		0	10	20	30	40	50
					Week

Titers	+ 95%CI
97-135
Anti-αSyn	LogDF,means

0.4 0.3 0.2 0.1

0.0

-0.1

Placebo

Group A

Group B

10	20	30	40	50
			Week

α

	Pan α-syn Ab			Oligomer-specific Ab			UB-312
(BD Biosciences, 610787)		(MJFR-14-6-4-2)			Aff. purified Ab
1	0.5	0.25	0.125	0.0625	1	0.5	0.25	0.125	0.0625	1	0.5	0.25	0.125	0.0625

MSA aggregates

PD aggregates

Rec. aggregates

Rec. monomer

α

α

		No Ab		Baseline IgG			Week 17 IgG

α